Anti-leukemia activity of 7-hydroxy-2-substituted-methyl-5H-oxazolo[3,2-a]pyrimidin-5-one derivatives.
The synthesis of new 7-hydroxy-2-substituted-methyl-5H-oxazolo[3,2-a]pyrimidin-5-ones derivatives, designed as structural bicyclic analogues of the iron chelator deferiprone, is described. They were tested for their ability to inhibit proliferation in human Bcr-Abl+ leukemia cells.
Guillon
Jean
J
EA 2962-Pharmacochimie, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux cedex, France.
Mamani-Matsuda
Maria
M
Massip
Stephane
S
Leger
Jean-Michel
JM
Thiolat
Denis
D
Mossalayi
Djavad
D
Jarry
Christian
C
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000737:chemistry / Q000494:pharmacology; D000077543:Deferiprone; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007502:Iron Chelating Agents / Q000737:chemistry; D020014:K562 Cells; D007938:Leukemia / Q000188:drug therapy; D015394:Molecular Structure; D010080:Oxazoles / Q000737:chemistry / Q000494:pharmacology; D011728:Pyridones / Q000737:chemistry; D011744:Pyrimidinones / Q000737:chemistry* / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D007502:Iron Chelating Agents; D010080:Oxazoles; D011728:Pyridones; D011744:Pyrimidinones; D000077543:Deferiprone